Results 61 to 70 of about 16,181 (154)
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 10, October 2026.It has been reported that eupatilin exerts cardioprotective effects after myocardial ischemia‐reperfusion injury (MIRI). This study further found that Eupatilin alleviated acute MIRI in rats by specifically inhibiting cyclooxygenase enzymes (COXs) and activating the Akt/GSK‐3β pathway, providing a theoretical basis for the application of eupatilin in ...
Min Guo, Qianqian Li, Lili Ji
wiley +1 more source
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 10, October 2026.ABSTRACT Background Recurrent stroke accounts for substantial morbidity and mortality worldwide, with up to 25% of ischemic strokes occurring in patients with prior strokes. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for secondary prevention after minor acute ischemic stroke (AIS) or high‐risk transient ischemic attack ...
Rachael M. Stone +8 more
wiley +1 more source
mBioInfections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including ...
Kirsten Leeten +22 more
doaj +1 more source
Cardiovascular Diabetology, 2019 Background Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE).
Robert S. Rosenson +5 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju +6 more
wiley +1 more source
Indian Heart Journal, 2019 Objective: We aimed to assess the efficacy and safety of ticagrelor compared to clopidogrel in Asian patients with acute coronary syndrome (ACS) in real-world practice.
Akhmetzhan Maratovich Galimzhanov +1 more
doaj +1 more source
Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca
ChemBioChem, Volume 27, Issue 17, 14 September 2026.Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale‐up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase.
Alba Diaz‐Rodriguez +4 more
wiley +1 more source
PLoS ONE, 2018 Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly 0.5-
Ann-Sofie Sandinge +3 more
doaj +1 more source
Journal of Pharmacy & Pharmaceutical Sciences, 2018 Purpose. This study aimed to explore the effects of ticagrelor (a P2Y12 receptor inhibitor) on interleukin (IL)-17 and myeloperoxidase (MPO) expression in coronary thrombus as well as on the coronary blood flow in ST-segment elevation myocardial ...
WenHua Li +8 more
doaj +1 more source
Ticagrelor – toward more efficient platelet inhibition and beyond
Therapeutics and Clinical Risk Management, 2018 Michał J Kubisa,1 Mateusz P Jezewski,1 Aleksandra Gasecka,2,3 Jolanta M Siller-Matula,4 Marek Postuła1 1Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), 21st Chair and Department of Cardiology,
Kubisa MJ +4 more
doaj